Phenyl heterocycles as COX-2 inhibitors
First Claim
Patent Images
1. A compound of formula I ##STR219## or a pharmaceutically acceptable salt thereof wherein:
- X--Y--Z-- is selected from the group consisting of;
(a) --CH2 CH2 CH2 --,(b) --C(O)CH2 CH2 --, and(c) --CH2 CH2 C(O)--,wherein side b is a double bond, and sides a an c are single bonds;
R1 is selected from the group consisting of(a) S(O)2 CH3,(b) S(O)2 NH2,(c) S(O)2 NHC(O)CF3,(d) S(O)(NH)CH3,(e) S(O)(NH)NH2,(f) S(O)(NH)NHC(O)CF3,(g) P(O)(CH3)OH, and(h) P(O)(CH3)NH2,R2 is selected from the group consisting of(a) C3, C4, C5, C6, and C7, cycloalkyl,(b) mono-, di- or tri-substituted phenyl wherein the substituent is selected from the group consisting of(1) hydrogen,(2) halo,(3) C1-6 alkoxy,(4) C1-6 alkylthio,(5) CN,(6) CF3,(7) C1-6 alkyl,(8) N3,(9) --CO2 H,(10) --CO2 --C1-4 alkyl,(11) --C(R5)(R6)--OH,(12) --C(R5)(R6)--O--C1-4 alkyl, and(13) --C1-6 alkyl-CO2 --R5 ;
(c) mono-, di- or tri-substituted heteroaryl wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one hetero atom which is S, O, or N, and optionally 1, 2, or 3 additional N atoms;
orthe heteroaryl is a monocyclic ring of 6 atoms, said ring having one hetero atom which is N, and optionally 1, 2 or 3 additional N atoms;
said substituents are selected from the group consisting of(1) hydrogen,(2) halo, including fluoro, chloro, bromo and iodo,(3) C1-6 alkyl,(4) C1-6 alkoxy,(5) C1-6 alkylthio,(6) CN,(7) CF3,(8) N3,(9) --C(R5)(R6)--OH, and(10) --C(R5)(R6)--O--C1-4 alkyl;
R5 and R6 are each independently selected from the group consisting of(a) hydrogen, and(b) C1-6 alkyl,or R5 and R6 or R7 and R8 together with the carbon to which they are attached form a monocyclic saturated carbon ring of 3, 4, 5, 6 or 7 atoms.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
252 Citations
18 Claims
-
1. A compound of formula I ##STR219## or a pharmaceutically acceptable salt thereof wherein:
- X--Y--Z-- is selected from the group consisting of;
(a) --CH2 CH2 CH2 --, (b) --C(O)CH2 CH2 --, and (c) --CH2 CH2 C(O)--, wherein side b is a double bond, and sides a an c are single bonds; R1 is selected from the group consisting of (a) S(O)2 CH3, (b) S(O)2 NH2, (c) S(O)2 NHC(O)CF3, (d) S(O)(NH)CH3, (e) S(O)(NH)NH2, (f) S(O)(NH)NHC(O)CF3, (g) P(O)(CH3)OH, and (h) P(O)(CH3)NH2, R2 is selected from the group consisting of (a) C3, C4, C5, C6, and C7, cycloalkyl, (b) mono-, di- or tri-substituted phenyl wherein the substituent is selected from the group consisting of (1) hydrogen, (2) halo, (3) C1-6 alkoxy, (4) C1-6 alkylthio, (5) CN, (6) CF3, (7) C1-6 alkyl, (8) N3, (9) --CO2 H, (10) --CO2 --C1-4 alkyl, (11) --C(R5)(R6)--OH, (12) --C(R5)(R6)--O--C1-4 alkyl, and (13) --C1-6 alkyl-CO2 --R5 ; (c) mono-, di- or tri-substituted heteroaryl wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one hetero atom which is S, O, or N, and optionally 1, 2, or 3 additional N atoms;
orthe heteroaryl is a monocyclic ring of 6 atoms, said ring having one hetero atom which is N, and optionally 1, 2 or 3 additional N atoms;
said substituents are selected from the group consisting of(1) hydrogen, (2) halo, including fluoro, chloro, bromo and iodo, (3) C1-6 alkyl, (4) C1-6 alkoxy, (5) C1-6 alkylthio, (6) CN, (7) CF3, (8) N3, (9) --C(R5)(R6)--OH, and (10) --C(R5)(R6)--O--C1-4 alkyl; R5 and R6 are each independently selected from the group consisting of (a) hydrogen, and (b) C1-6 alkyl, or R5 and R6 or R7 and R8 together with the carbon to which they are attached form a monocyclic saturated carbon ring of 3, 4, 5, 6 or 7 atoms. - View Dependent Claims (2, 3, 4, 5, 6, 7, 13, 15, 16, 17, 18)
- X--Y--Z-- is selected from the group consisting of;
-
8. A compound according to claim 8 wherein R2 is a mono- or di-substituted heteroaryl wherein heteroaryl is selected from the group consisting of
(1) 2-furanyl, (2) 3-furanyl, (3) 2-thienyl, (4) 3-thienyl, (5) 3-isoxazolyl, (6) 4-isoxazolyl, (7) 5-isoxazolyl, (8) 3-isothiazolyl, (9) 4-isothiazolyl, (10) 5-isothiazolyl, (11) 2-oxazolyl, (12) 4-oxazolyl, (13) 5-oxazolyl, (14) 2-thiazolyl, (15) 4-thiazolyl, (16) 5-thiazolyl, (17) 1,2,3-thiadiazol-4-yl, (18) 1,2,3-thiadiazol-5-yl, (19) 1,2,4-thiadiazol-3-yl, (20) 1,2,4-thiadiazol-5-yl, (21) 1,3,4-thiadiazol-2-yl, (22) 1,2,5-thiadiazol-3-yl, (23) 1,2,3-oxadiazol-4-yl, (24) 1,2,3-oxadiazol-5-yl, (25) 1,2,4-oxadiazol-3-yl, (26) 1,2,4-oxadiazol-5-yl, (27) 1,3,4-oxadiazol-2-yl, (28) 1,2,5-oxadiazol-3-yl, (29) pyrazol-4-yl, (30) pyrazol-5-yl, (31) 1,2,3-triadiazol-4-yl, (32) 1,2,3-triadiazol-5-yl, (33) 1,2,4-triadiazol-3-yl, (34) 1,2,4-triadiazol-5-yl, (35) 1,2-diazinyl, (36) 1,3-diazinyl, (37) 1,4-diazinyl, (38) 1,2,3,4-tetrazin-5-yl, (39) 1,2,4,5-tetrazin-4-yl, (40) 1,3,4,5-tetrazin-2-yl, and (41) 1,2,3,5-tetrazin-4-yl.
-
14. A compound which is ##STR221##
Specification